Alkem Laboratories
Alkem Laboratories Limited, a prominent player in the pharmaceutical industry, is headquartered in Mumbai, India. Founded in 1973, the company has established a strong presence in various operational regions, including North America, Europe, and Asia. Alkem is renowned for its extensive portfolio of generic and branded formulations, as well as active pharmaceutical ingredients (APIs), catering to diverse therapeutic areas such as anti-infectives, cardiology, and gastroenterology. With a commitment to quality and innovation, Alkem Laboratories has achieved significant milestones, including numerous approvals from regulatory authorities worldwide. The company is recognised for its robust research and development capabilities, which underpin its unique product offerings. Alkem's market position is further solidified by its consistent growth and notable achievements, making it a trusted name in the global healthcare landscape.
DitchCarbon Score
How does Alkem Laboratories's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Alkem Laboratories's score of 19 is higher than 61% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Alkem Laboratories's reported carbon emissions
In 2024, Alkem Laboratories reported total carbon emissions of approximately 101,568,000 kg CO2e, comprising about 19,249,000 kg CO2e from Scope 1 and about 82,319,000 kg CO2e from Scope 2 emissions. This represents a slight increase from 2023, where total emissions were approximately 94,274,000 kg CO2e, with Scope 1 emissions at about 15,773,000 kg CO2e and Scope 2 emissions at about 78,502,000 kg CO2e. In 2022, the company recorded total emissions of approximately 138,400,000 kg CO2e, with Scope 1 emissions at about 31,367,000 kg CO2e and Scope 2 emissions at about 107,033,000 kg CO2e. Despite these figures, Alkem Laboratories has not disclosed specific reduction targets or initiatives aimed at decreasing their carbon footprint. The absence of defined climate pledges or science-based targets indicates a need for further commitment to sustainability practices within the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 31,367,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 107,033,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Alkem Laboratories is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
